Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Rheumatoid Arthritis

  Free Subscription


22.04.2019

5 Arthritis Res Ther
4 J Rheumatol
1 PLoS One
1 Z Rheumatol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Arthritis Res Ther

  1. WINTHROP KL, Bingham CO 3rd, Komocsar WJ, Bradley J, et al
    Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy.
    Arthritis Res Ther. 2019;21:102.
    PubMed     Text format     Abstract available

  2. POLISKA S, Besenyei T, Vegh E, Hamar A, et al
    Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:94.
    PubMed     Text format     Abstract available

  3. TANAKA Y, Wada K, Takahashi Y, Hagino O, et al
    Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.
    Arthritis Res Ther. 2019;21:99.
    PubMed     Text format     Abstract available

  4. SUN X, Deng X, Xie W, Wang L, et al
    The agreement between ultrasound-determined joint inflammation and clinical signs in patients with rheumatoid arthritis.
    Arthritis Res Ther. 2019;21:100.
    PubMed     Text format     Abstract available

  5. TAYLOR PC, Saurigny D, Vencovsky J, Takeuchi T, et al
    Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or
    Arthritis Res Ther. 2019;21:101.
    PubMed     Text format     Abstract available


    J Rheumatol

  6. BERENS HM, Polinski KJ, Mikuls TR, Khatter S, et al
    Anti-CCP3.1 and Anti-CCP-IgA Are Associated with Increasing Age in Individuals Without Rheumatoid Arthritis.
    J Rheumatol. 2019 Apr 15. pii: jrheum.180897. doi: 10.3899/jrheum.180897.
    PubMed     Text format     Abstract available

  7. LAU AN, Thorne JC, Movahedi M, Rampakakis E, et al
    Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results.
    J Rheumatol. 2019 Apr 15. pii: jrheum.180486. doi: 10.3899/jrheum.180486.
    PubMed     Text format     Abstract available

  8. WEINSTEIN A, McEvilly B, Dervieux T
    Reevaluating Serologic Markers of Poor Prognostic Factors in Rheumatoid Arthritis.
    J Rheumatol. 2019 Apr 15. pii: jrheum.181246. doi: 10.3899/jrheum.181246.
    PubMed     Text format     Abstract available

  9. DURAND C, Eldoma M, Marshall DA, Bansback N, et al
    Patient preferences for disease modifying anti-rheumatic drug treatment in rheumatoid arthritis: A systematic review.
    J Rheumatol. 2019 Apr 15. pii: jrheum.181165. doi: 10.3899/jrheum.181165.
    PubMed     Text format     Abstract available


    PLoS One

  10. SUNG YK, Yoshida K, Prince FHM, Frits ML, et al
    Prevalence and predictors for sustained remission in rheumatoid arthritis.
    PLoS One. 2019;14:e0214981.
    PubMed     Text format     Abstract available


    Z Rheumatol

  11. SCHNEIDER M, Burmester GR
    [Tight control-Demand for short term control of rheumatoid arthritis].
    Z Rheumatol. 2019 Apr 18. pii: 10.1007/s00393-019-0631.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Rheumatoid Arthritis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: